Case study: Read how Vivo provides fast, actionable insights to global trials https://lnkd.in/gqPWzEVz
OmniScience
软件开发
Houston，Texas 2,740 位关注者
We're a leading AI organization advancing clinical R&D missions with unparalleled expertise in clinical data science.
关于我们
OmniScience is a leading AI organization that advances clinical R&D missions with unparalleled expertise clinical data science. Our passion for improving patient lives has produced a celebrated track record addressing some of the most pressing areas in life science with our platforms Vivo, the platform for modern clinical development teams, and Ergo, generative AI for clinical strategy intelligence. If you would like to discuss how our platforms or bespoke work in data science can help you, reach us at [email protected].
- 网站
-
https://www.omniscience.bio
OmniScience的外部链接
- 所属行业
- 软件开发
- 规模
- 11-50 人
- 总部
- Houston，Texas
- 类型
- 私人持股
- 创立
- 2017
- 领域
- Digital Biomarkers、 Digital Health、Medical Devices、Genomics、 Multi Omics、 Neuroscience、Human Behavior、 Proteomics、Data Science、Machine Learning和Clinical Trials
地点
-
主要
获取路线
2450 Holcombe Blvd
1220
US，Texas，Houston，77021
OmniScience员工
-
Colin Hendricks
Software CTO
-
Blair Garrou
VC @ Mercury | Adjunct Prof @ Rice | AI/ML Software in Retail and Fintech
-
Carla Holloway
Marketing Strategist | Team Leader & Internal Communications Champion | Customer Experience Advocate | Healthcare, Life Science, & Pharma Industry…
-
Julie Mocko
Director of Product Design - Creating Platforms Powered by GenAI for Clinical Trial Data Intelligence
动态
-
Imagine having instant answers to your most pressing clinical trial questions - no spreadsheets, no programming, no delays. Ask Vivo makes it possible. Powered by genAI, it delivers real-time insights across operations, safety, and clinical, eliminating friction and accelerating decision-making. Discover how Ask Vivo is redefining trial intelligence. Watch the full video here ?? https://lnkd.in/gbbRVWur
-
OmniScience is proud to be a sponsor of and contributor to the DiMe initiative "Unlocking impact through investment: Building the business case for digital endpoints." We are excited to be working toward a future where #digitalmeasures result in more patient-centric and data-driven clinical trials improving the overall clinical trial process by driving efficiency, reducing costs, and improving patient outcomes. It has been a pleasure to work with other industry leaders towards this unified vision and are thankful to DiMe for bringing everyone together. After 6 months of work we are looking forward to the culmination of this work in the public launch event on Wed., Mar. 26, at 11 a.m. ET
??? Join our upcoming public launch event on Wed., Mar. 26, at 11 a.m. ET: "Unlocking impact through investment: Building the business case for digital endpoints." We’ll unveil DATAcc by DiMe’s new resources designed to help you prove the value of digital endpoints in clinical trials. #Digitalmeasures provide unprecedented insights into people’s symptoms and experiences, advancing our understanding of disease. Leveraging digital endpoints can make clinical trials more patient-centric, data-driven, and adaptable—and these new resources empower you to unlock their full potential. What you’ll learn: ?? Innovative methods to evaluate the ROI of digital endpoints ?? How to make the case for continued investment in digital strategies that align with your business goals ?? The role of digital endpoints in reducing clinical trial costs and improving patient outcomes and operational efficiency ?? Insights from DiMe’s partnership with the Tufts Center for the Study of Drug Development and industry leaders demonstrating the measurable value of digital endpoints Don’t miss your chance to access the resources that will drive innovation, enhance clinical trial outcomes, and accelerate the development of life-changing therapies. ?? Save your spot now! https://lnkd.in/dEYtTQ47 Eastern Virginia Medical School Modality.AI Koneksa Evinova Merck
-
-
OmniScience is proud to have the guidance of industry leaders Linda Blackerby and Nicola Marlin on our Board of Directors. With deep expertise in pharma intelligence and a track record of driving strategic growth - including leading Citeline to a $2.6B exit - Linda and Nicky bring invaluable insight as we scale the impact of GenAI in clinical trial operations. From day one, they recognized OmniScience as a game changer in accelerating drug development and improving trial success. Learn more about their backgrounds and why they joined our board in this Q&A post: ?? https://lnkd.in/gbqjMsXq
-
Clinical trial teams are drowning in data but starved for insights. Vivo changes that. It unifies data across sources, giving teams the real-time visibility they need to make informed decisions and drive better outcomes. Here, OmniScience CEO Angela Holmes shares why the future of clinical trials starts with harnessing the power of data. Watch the full video here ?? https://lnkd.in/gbbRVWur
-
?? Automate Data Integration: Vivo unifies all of your clinical trial data into a single portal, reducing manual effort, providing real-time oversight, and ensuring data consistency. Vivo works with every source, including EDCs, COAs/PROs, labs, and other data sources. Revolutionize your clinical trials with Vivo:? → https://lnkd.in/gkbaQ4aC #clinicaltrials #clinicalresearch
-
-
OmniScience转发了
We are excited to join forces with OmniScience to accelerate clinical development in oncology.
We’re thrilled to announce our partnership with Integro Theranostics to improve cancer clinical study outcomes. By integrating OmniScience’s AI-powered solutions with Integro’s innovative imaging agent, we’re aiming to improve surgical precision and accelerate clinical development in oncology. Together, we’re committed to advancing patient care through cutting-edge technology. More here ?? https://lnkd.in/gGUu4AmY #oncology #clinicaltrials #aiinhealthcare
-
OmniScience转发了
It has been my privilege to work with our Board Directors Linda Blackerby and Nicola Marlin. Linda and Nicky bring incredible expertise from their work building Citeline as the leading pharma intelligence product, leading to a $2.6B exit. They believed from the beginning that OmniScience would be a game changer and would set the standard on using genAI in clinical trial operations to improve outcomes and increase probability of success. Excited to share more about their backgrounds and why they joined our board. Thank you Linda and Nicky for your leadership on our OmniScience board of directors! https://lnkd.in/gCrhyj-P
-
Vivo is transforming how clinical trial teams manage their data, no matter their starting point. From emerging biopharma innovators to established pharma organizations, Vivo is a tactical and strategic partner that empowers clinical trial teams to move beyond spreadsheets. In this clip, we highlight a global Phase 2 study with 200 participants, 6 data sources, and 90 sites. Vivo supported their team at every level, fundamentally changing how they approached clinical trial data and achieving remarkable results. Watch the full video here ?? https://lnkd.in/grqkDckk
-
OmniScience转发了
I’m honored to be nominated for the Women in Artificial Intelligence Awards North America 2025! This recognition highlights the incredible contributions of women advancing AI in Canada, the USA, and Mexico. Thank you Women in AI! #waiawards? #womeninai
-